Open access
Open access
Powered by Google Translator Translator

Pediatrics - Pulmonology

[Preprint] Study confirms children’s extremely low risk of death from Covid-19 – “99·995% of children and young people with a positive SARS-CoV-2 test survived”.

12 Jul, 2021 | 03:12h | UTC

Original study (preprint): Deaths in Children and Young People in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data – National Child Mortality Database / Public Health England

Commentaries: Risks of severe illness in children from COVID-19 shown to be very low in largest study yet – University of Liverpool AND Covid: Children’s extremely low risk confirmed by study – BBC

Related study from the same group (preprint): Risk factors for intensive care admission and death amongst children and young people admitted to hospital with COVID-19 and PIMS-TS in England during the first pandemic year – medRxiv

 

Review: Advances in the diagnosis and treatment of primary ciliary dyskinesia.

21 Jun, 2021 | 08:27h | UTC

Advances in the Diagnosis and Treatment of Primary Ciliary Dyskinesia: A Review – JAMA Otolaryngology – Head & Neck Surgery (free for a limited period)

 

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

18 Jun, 2021 | 08:36h | UTC

Treatment of Multisystem Inflammatory Syndrome in Children – New England Journal of Medicine

Editorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics

Commentaries: Steroids may be effective treatment for COVID-19 complications in children – Imperial College London AND Expert reaction to study looking at treatments for COVID-19 complications in children – Science Media Centre

 

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

18 Jun, 2021 | 08:35h | UTC

Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes – New England Journal of Medicine

Editorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics

 

Audio Interview: potential treatments for children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19.

18 Jun, 2021 | 08:33h | UTC

Audio Interview: Covid-19 in Children – New England Journal of Medicine

 

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

14 Jun, 2021 | 08:48h | UTC

Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2 – JAMA Network Open

Commentary: MIS-C Incidence 316 Persons Per 1 Million SARS-CoV-2 Infections – HealthDay

 

Commentary on Twitter

 

In youth, COVID-19 causes more complications than flu; fatality is rare.

9 Jun, 2021 | 08:23h | UTC

In youth, COVID-19 causes more complications than flu; fatality is rare – Columbia University Irving Medical Center

Original study: 30-Day Outcomes of Children and Adolescents With COVID-19: An International Experience – Pediatrics

 

Underlying medical conditions associated with severe COVID-19 illness among children – the strongest risk factors for hospitalization were chronic and complex chronic diseases, type 1 diabetes, and obesity.

8 Jun, 2021 | 09:37h | UTC

Underlying Medical Conditions Associated With Severe COVID-19 Illness Among Children – JAMA Network Open

Commentaries: Underlying illness, respiratory infection raise risk for severe COVID in kids – CIDRAP AND COVID-19 in Children—Not Just Little Adults – JAMA Network Open

 

Commentary on Twitter

 

Synopsis | Updates to the Pediatrics Asthma Management Guidelines.

8 Jun, 2021 | 09:22h | UTC

Updates to the Pediatrics Asthma Management Guidelines – JAMA Pediatrics (free for a limited period)

Original Guideline: 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group

 

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

3 Jun, 2021 | 11:06h | UTC

6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study – The Lancet Child & Adolescent Health

Commentary: Most severe effects of MIS-C in children typically resolve within six months, new research suggests – CNN AND Children who developed a rare inflammation disease after COVID-19 are mostly better after 6 months, but some still suffer fatigue and anxiety, a small UK study found – Insider AND Most severe effects of PIMS-TS resolved at six months – HealthDay

 

Commentary on Twitter

 

RCT: Among children with protracted bacterial bronchitis, a 4-week course of amoxicillin–clavulanate is not better than a 2-week course in achieving clinical cure by 28 days.

31 May, 2021 | 08:02h | UTC

Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children (DACS): a multi-centre, double blind, randomised controlled trial – The Lancet Respiratory Medicine

Commentary: Four weeks of antibiotics for kids’ chronic cough no better than 2, study finds – CIDRAP

 

Commentary on Twitter

 

ERS clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years.

20 May, 2021 | 08:21h | UTC

European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years – European Respiratory Journal

 

Cohort study of 12,306 pediatric COVID-19 patients finds only 16.5% presented with typical respiratory symptoms (cough, dyspnea). 13.9% had GI symptoms, 8.1% had dermatological symptoms (rash), 4.8% had neurological (headache), and 18.8% had other non-specific symptoms (fever, malaise, myalgia, arthralgia and disturbances of smell or taste).

14 May, 2021 | 08:48h | UTC

A retrospective cohort study of 12,306 pediatric COVID-19 patients in the United States – Scientific Reports

Commentary: COVID-19: Majority of infected children may not show typical symptoms – Nature Publishing Group

 

Commentary on Twitter

 

Systematic review: Combination fixed‐dose beta-agonist and steroid inhaler as required is clinically effective in adults and adolescents with mild asthma.

14 May, 2021 | 08:23h | UTC

Combination fixed‐dose beta agonist and steroid inhaler as required for adults or children with mild asthma – Cochrane Library

Summary: Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma – Cochrane Library

 

RCT: Tezepelumab can reduce exacerbations in adults and adolescents with severe, uncontrolled asthma.

14 May, 2021 | 08:25h | UTC

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma – New England Journal of Medicine

Commentary: New drug shows promise against tough-to-manage asthma – MedicalXpress

 

Pfizer COVID-19 shot expanded to US children as young as 12.

12 May, 2021 | 08:53h | UTC

Pfizer COVID-19 shot expanded to US children as young as 12 – Associated Press

Counterpoint: Covid vaccines for children should not get emergency use authorization – The BMJ Opinion

Commentaries: Covid-19: FDA authorises Pfizer vaccine for children 12-15 – The BMJ AND Expert reaction to U.S. FDA authorising Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents – Science Media Centre

 

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

22 Apr, 2021 | 08:40h | UTC

Post-acute COVID-19 outcomes in children with mild and asymptomatic disease – The Lancet Child & Adolescent Health

 

Commentaries on Twitter

 

Characteristics and Disease Severity of US Children and Adolescents Diagnosed With COVID-19

14 Apr, 2021 | 01:59h | UTC

Characteristics and Disease Severity of US Children and Adolescents Diagnosed With COVID-19 – JAMA Network Open

Commentary: CDC: 1 in 3 children hospitalized with COVID-19 requires treatment in ICU – UPI AND 12% of Children with COVID Are Hospitalized: Study – WebMD

 

Commentary on Twitter

 

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

7 Apr, 2021 | 01:52h | UTC

Editorial: Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When – JAMA Pediatrics

Original study: Trends in Geographic and Temporal Distribution of US Children With Multisystem Inflammatory Syndrome During the COVID-19 Pandemic – JAMA Pediatrics

Commentaries: New findings in COVID-related kids’ syndrome, Kawasaki disease – CIDRAP AND Most kids with serious inflammatory illness had mild COVID – Associated Press

 

[Press release – not published yet] Pfizer-BioNTech vaccine 100% effective against Covid-19 in adolescents

1 Apr, 2021 | 03:52h | UTC

Press release: Pfizer-BioNTech Announce Positive Topline Results Of Pivotal Covid-19 Vaccine Study In Adolescents

Commentaries: The Pfizer-BioNTech Vaccine Is Said to Be Powerfully Protective in Adolescents – The New York Times AND Covid: Children ‘well protected by Pfizer vaccine’ – BBC AND Pfizer Says COVID-19 Vaccine Shows ‘100% Efficacy’ In Adolescents – NPR AND Pfizer says its COVID-19 vaccine protects younger teens – Associated Press AND Pfizer and BioNTech say vaccine prevents Covid-19 in adolescents – STAT

 

Commentaries on Twitter

 

CDC Guidance for schools says students can now stay 3 feet apart, rather than 6

21 Mar, 2021 | 22:07h | UTC

CDC Guidance: CDC Updates Operational Strategy for K-12 Schools to Reflect New Evidence on Physical Distance in Classrooms – Centers for Disease Control and Prevention

See also: Operational Strategy for K-12 Schools through Phased Prevention – Centers for Disease Control and Prevention

Commentaries: CDC Says Schools Can Now Space Students 3 Feet Apart, Rather Than 6 – NPR AND CDC updates COVID school guidance, OKs 3-feet distancing – CIDRAP

Related: Cohort study: Effectiveness of three vs. six feet of physical distancing for controlling spread of COVID-19 among primary and secondary students and staff (study and commentary)

 

Commentaries on Twitter

 

Clinician Guide to COVID-19 diagnostics in children

21 Mar, 2021 | 21:48h | UTC

Clinician guide to COVID-19 diagnostics – ADC Education & Practice

 

Study: Children and young people remain at low risk of COVID-19 mortality

11 Mar, 2021 | 08:28h | UTC

Children and young people remain at low risk of COVID-19 mortality – The Lancet Child and Adolescent Health

 

RCT: 5 days of high-dose amoxicillin therapy noninferior to 10 days for the treatment of pediatric community-acquired pneumonia

9 Mar, 2021 | 02:29h | UTC

Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial – JAMA Pediatrics (free for a limited period)

Editorial: Rightsizing Treatment for Pneumonia in Children

Commentary: Five days of antibiotics fine for children with pneumonia – McMaster University

 

Commentary on Twitter (thread – click for more)

 

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

2 Mar, 2021 | 02:11h | UTC

Acute covid-19 and multisystem inflammatory syndrome in children – The BMJ

 

Commentary on Twitter

 

Stay Updated in Your Specialty

No spam, just news.